Belite Bio, Inc
BLTENASDAQHealthcare● Active
$139.63
$-3.72(-2.60%)
Market Cap$5.6B
P/E Ratio—
52W High$200
52W Low$56.1
Belite Bio, Inc (BLTE) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
BLTE · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 20, 2026EPS Actual
-$0.34
Est. -$0.60 · +43.3%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 20, 2026
After Market Close
▲ Beat EPS✓ 2-Quarter EPS Beat Streak
BLTE reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.58B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.58B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 10, 2026 | -$0.73 | — | — | — | — | — |
| ▲ Q2 FY2026 | May 20, 2026 | -$0.60 | -$0.34 | +43.3% | — | — | — |
| ▲ Q1 FY2026 | Mar 2, 2026 | -$0.56 | -$0.38 | +32.1% | — | $0.02B | — |
| ▼ Q4 FY2025 | Nov 10, 2025 | -$0.53 | -$0.65 | -22.6% | — | — | — |
| ▼ Q3 FY2025 | Aug 11, 2025 | -$0.47 | -$0.50 | -6.4% | — | — | — |
| ▼ Q2 FY2025 | May 13, 2025 | -$0.36 | -$0.45 | -25.0% | — | — | — |
| ▼ Q1 FY2025 | Mar 17, 2025 | -$0.30 | -$0.32 | -6.7% | — | — | — |
| ▲ Q4 FY2024 | Nov 12, 2024 | -$0.30 | -$0.28 | +6.7% | — | — | — |
Q3 FY2026
Aug 10, 2026
EPS Actual
—
EPS Est.
-$0.73
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 20, 2026Beat
EPS Actual
-$0.34
EPS Est.
-$0.60
EPS Surpr.
+43.3%
Revenue
—
Q1 FY2026
Mar 2, 2026Beat
EPS Actual
-$0.38
EPS Est.
-$0.56
EPS Surpr.
+32.1%
Revenue
—
Q4 FY2025
Nov 10, 2025Miss
EPS Actual
-$0.65
EPS Est.
-$0.53
EPS Surpr.
-22.6%
Revenue
—
Q3 FY2025
Aug 11, 2025Miss
EPS Actual
-$0.50
EPS Est.
-$0.47
EPS Surpr.
-6.4%
Revenue
—
Q2 FY2025
May 13, 2025Miss
EPS Actual
-$0.45
EPS Est.
-$0.36
EPS Surpr.
-25.0%
Revenue
—
Q1 FY2025
Mar 17, 2025Miss
EPS Actual
-$0.32
EPS Est.
-$0.30
EPS Surpr.
-6.7%
Revenue
—
Q4 FY2024
Nov 12, 2024Beat
EPS Actual
-$0.28
EPS Est.
-$0.30
EPS Surpr.
+6.7%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.00 | $0.00 | $0.00 | 3 |
| Q3 FY2028 | $0.00 | $0.00 | $0.00 | 2 |
| Q2 FY2028 | $0.00 | $0.00 | $0.00 | 2 |
| Q1 FY2028 | $0.00 | $0.00 | $0.00 | 3 |
| Q4 FY2027 | $0.84 | $0.84 | $0.84 | 2 |
| Q3 FY2027 | $-0.01 | $-0.01 | $-0.01 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.1B | $0.1B | $0.1B | 1 |
| Q3 FY2028 | $0.1B | $0.1B | $0.1B | 1 |
| Q2 FY2028 | $0.1B | $0.1B | $0.1B | 1 |
| Q1 FY2028 | $0.1B | $0.1B | $0.1B | 1 |
| Q4 FY2027 | $0.1B | $0.1B | $0.1B | 1 |
| Q3 FY2027 | $0.1B | $0.1B | $0.1B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 20, 2026 | +43.3% | $139.70 | $143.36 | +2.62% |
| ▲ Q1 FY2026 | Mar 2, 2026 | +32.1% | $190.30 | $177.58 | -6.68% |
| ▼ Q4 FY2025 | Nov 10, 2025 | -22.6% | $113.19 | $117.34 | +3.67% |
| ▼ Q3 FY2025 | Aug 11, 2025 | -6.4% | $69.88 | $69.50 | -0.54% |
| ▼ Q2 FY2025 | May 13, 2025 | -25.0% | $61.99 | $60.89 | -1.77% |
| ▼ Q1 FY2025 | Mar 17, 2025 | -6.7% | $67.44 | $67.81 | +0.55% |
| ▲ Q4 FY2024 | Nov 12, 2024 | +6.7% | $78.64 | $81.15 | +3.19% |
| ▼ Q3 FY2024 | Aug 9, 2024 | -10.7% | $49.24 | $49.48 | +0.49% |
Q2 FY2026+2.62%
Report Date
May 20, 2026
EPS Beat/Miss
+43.3%
Price Before
$139.70
Price After
$143.36
Q1 FY2026-6.68%
Report Date
Mar 2, 2026
EPS Beat/Miss
+32.1%
Price Before
$190.30
Price After
$177.58
Q4 FY2025+3.67%
Report Date
Nov 10, 2025
EPS Beat/Miss
-22.6%
Price Before
$113.19
Price After
$117.34
Q3 FY2025-0.54%
Report Date
Aug 11, 2025
EPS Beat/Miss
-6.4%
Price Before
$69.88
Price After
$69.50
Q2 FY2025-1.77%
Report Date
May 13, 2025
EPS Beat/Miss
-25.0%
Price Before
$61.99
Price After
$60.89
Q1 FY2025+0.55%
Report Date
Mar 17, 2025
EPS Beat/Miss
-6.7%
Price Before
$67.44
Price After
$67.81
Q4 FY2024+3.19%
Report Date
Nov 12, 2024
EPS Beat/Miss
+6.7%
Price Before
$78.64
Price After
$81.15
Q3 FY2024+0.49%
Report Date
Aug 9, 2024
EPS Beat/Miss
-10.7%
Price Before
$49.24
Price After
$49.48
Avg Beat Reaction-0.29%
Avg Miss Reaction+0.48%
Beat Rate3 / 8 quarters
Largest Move-6.68% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: BLTE ends December
Belite Bio, Inc (BLTE) most recently reported earnings on May 20, 2026 for Q2 FY2026, posting EPS of $-0.34 — beating the analyst consensus of $-0.60 by +43.3%. BLTE has beaten EPS estimates for 2 consecutive quarters. The next BLTE earnings date is expected around September 1, 2026.
Each quarter, investors track BLTE earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. BLTE revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
BLTE's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
BLTE earnings · 5 questionsBelite Bio, Inc's next earnings report is expected around September 1, 2026. BLTE typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; BLTE historically reports after market close (AMC).
BLTE earnings datewhen is BLTE earningsBLTE next earnings datewhen does BLTE report earningsBLTE earnings calendar
▸ Source: FMP · Belite Bio, Inc SEC filings · US GAAP · Belite Bio, Inc SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026